Biocatalysis in synthesizing pharmaceutical intermediates and active pharmaceutical ingredients (APIs) is becoming an increasingly important part of the toolbox of fine chemical and pharmaceutical companies. Biocatalysts are bringing new and potentially better transformation properties which are helping to advance innovation, and improve development and manufacturing of pharmaceutical processes.
Biocatalysts make important synthetic reactions proceed more rapidly and often enable the formation of complex structures in fewer steps with greater selectivity. Biocatalysts, typically enzymes, offer additional advantages. They catalyze reactions under mild conditions and thus consume less energy. They do not require the use of heavy or toxic metals, and in some cases enable the avoidance of hazardous raw materials. In addition, such reactions can often be carried out in water rather than organic solvents, and they tend to generate less waste.
Typically the pharmaceutical industry has been satisfied with using bacterial enzyme production platforms, such as Escherichia coli (E. coli) which allow for the rapid production of efficient manufacturing of enzymes at industrial-scale. However, we believe there are certain potential biocatalysts that may need to be manufactured at higher yields, and lower costs and believe that our C1 technology may be a better option than E. coli or other expression platforms currently being used by the pharmaceutical industry for such future biocatalysts.